Orchid's Q1 Sales Rise 12 Percent as Losses Slide 75 Percent on Reorg | GenomeWeb
NEW YORK (GenomeWeb News) — Orchid Cellmark today said first-quarter revenue rose 12 percent, R&D spending inched up a hair, and losses receded 75 percent.
 
Total receipts for the three months ended March 31 increased to $14.1 million from $12.6 million year over year due mostly to an increase in forensic casework in the US and UK.
 
However, those gains were offset in part by a decrease in testing services to the Federal Bureau of Investigation.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.